Butanol fraction of Parkia biglobosa (Jacq.) G. Don leaves enhance pancreatic β-cell functions, stimulates insulin secretion and ameliorates other type 2 diabetes-associated complications in rats

Autor: James Dama Habila, Md. Shahidul Islam, Mohammed Auwal Ibrahim, Neil A. Koorbanally
Rok vydání: 2016
Předmět:
Blood Glucose
Male
Butanols
medicine.medical_treatment
Type 2 diabetes
030226 pharmacology & pharmacy
Parkia biglobosa
Rats
Sprague-Dawley
chemistry.chemical_compound
0302 clinical medicine
Insulin-Secreting Cells
Drug Discovery
Insulin
Traditional medicine
biology
Fabaceae
Bioactive compound
Togo
030220 oncology & carcinogenesis
medicine.drug
medicine.medical_specialty
Intraperitoneal injection
Nigeria
Diabetes Mellitus
Experimental
Diabetes Complications
03 medical and health sciences
Diabetes mellitus
Internal medicine
medicine
Animals
Hypoglycemic Agents
Dyslipidemias
Pharmacology
Plant Extracts
business.industry
alpha-Glucosidases
Fructose
Glucose Tolerance Test
medicine.disease
Streptozotocin
biology.organism_classification
Liver Glycogen
Rats
Plant Leaves
Endocrinology
Diabetes Mellitus
Type 2
chemistry
Insulin Resistance
alpha-Amylases
business
Zdroj: Journal of Ethnopharmacology. 183:103-111
ISSN: 0378-8741
Popis: Ethnopharmacological surveys have reported that Parkia biglobosa (Jacq.) G. Don (Leguminosae) is among the plants commonly used in the traditional management of diabetes mellitus in Nigeria and Togo.This study investigated the anti-diabetic activity of the butanol fraction of P. biglobosa leaves (PBBF) in a type 2 diabetes (T2D) model of rats and a possible bioactive compound in the fraction.T2D was induced by feeding rats with a 10% fructose solution ad libitum for two weeks followed by an intraperitoneal injection of 40mg/kg body weight streptozotocin and the animals were orally treated with 150 and 300mg/kg BW of the PBBF for five days in a week. Another group of rats was non-diabetic but similarly administered with 300mg/kg BW of the PBBF. Food and fluid intakes, body weight changes and blood glucose levels were monitored during the experiment while other relevant diabetes-associated parameters were measured at the end of the experiment.The PBBF treatments significantly (P0.05) decreased the blood glucose levels and improved the glucose tolerance ability compared to untreated diabetic rats. Furthermore, the treatments were found to improve pancreatic β cell function (HOMA-β), stimulate insulin secretions, decrease insulin resistance (HOMA-IR), restore liver glycogen, ameliorate serum dyslipidaemia and prevent hepatic and renal damages compared to untreated diabetic rats. Phytochemical analysis of the fraction led to the isolation of lupeol which inhibited α-glucosidase and α-amylase in non-competitive and uncompetitive inhibition patterns respectively.It was concluded that PBBF possessed remarkable anti-T2D activity which is mediated through modulation of β-cell function and stimulation of insulin secretion and the lower dose (150mg/kg BW) was found optimum for anti-T2D activity compared to the high dose (300mg/kg BW) in this study.
Databáze: OpenAIRE
Externí odkaz: